 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...12131415161718192021222324 |
- | ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - Dec 10, 2013
P2, N=400, Recruiting, Sponsor: Gilead Sciences
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Sofosbuvir/Ledipasvir (clinicaltrials.gov) - Dec 10, 2013
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Nov 17, 2013
P2, N=100, Enrolling by invitation, Sponsor: Gilead Sciences
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection (clinicaltrials.gov) - Nov 17, 2013
P2, N=35, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| radalbuvir (GS-9669) / Gilead
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Nov 12, 2013
P2, N=90, Active, not recruiting, Sponsor: Gilead Sciences
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Efficacy and Safety of Sofosbuvir/Ledipasvir (clinicaltrials.gov) - Nov 3, 2013
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination (clinicaltrials.gov) - Oct 16, 2013
P2, N=150, Active, not recruiting, Sponsor: Gilead Sciences
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency (clinicaltrials.gov) - Oct 7, 2013
P2, N=40, Recruiting, Sponsor: Gilead Sciences
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency (clinicaltrials.gov) - Oct 5, 2013
P2, N=40, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - Sep 8, 2013
P2, N=400, Recruiting, Sponsor: Gilead Sciences
- ||| radalbuvir (GS-9669) / Gilead
Trial initiation date: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection (clinicaltrials.gov) - Aug 26, 2013
P2, N=410, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Initiation date: Apr 2013 --> Aug 2013
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection (clinicaltrials.gov) - Aug 15, 2013
P2, N=35, Active, not recruiting, Sponsor: Gilead Sciences
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV (clinicaltrials.gov) - Jun 16, 2013
P3, N=800, Active, not recruiting, Sponsor: Gilead Sciences
Initiation date: Apr 2013 --> Aug 2013 Recruiting --> Active, not recruiting
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - May 8, 2013
P3, N=647, Completed, Sponsor: Gilead Sciences
- ||||| radalbuvir (GS-9669) / Gilead
New P2 trial: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection (clinicaltrials.gov) - Apr 7, 2013
P2, N=410, Recruiting, Sponsor: Gilead Sciences
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: ION-2: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Jan 13, 2013
P3, N=441, Completed, Sponsor: Gilead Sciences
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment change: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) (clinicaltrials.gov) - Dec 6, 2012
P2, N=100, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting N=60 --> 100
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) (clinicaltrials.gov) - Nov 13, 2012
P2, N=100, Completed, Sponsor: Gilead Sciences
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV (clinicaltrials.gov) - Oct 3, 2012
P3, N=800, Active, not recruiting, Sponsor: Gilead Sciences